



## Anticancer Activity of Flavone of *Excoecaria agallocha* in Cytotoxicity Studies Using Hela Cells

KARNATI RAJESWARI<sup>1,\*</sup>, T. BHASKARA RAO<sup>1</sup>, G.V.R. SHARMA<sup>2</sup> and R. MURALI KRISHNA<sup>3</sup>

<sup>1</sup>Department of Chemistry, K L University, Guntur-522 502, India

<sup>2</sup>Department of Chemistry, GITAM University, Rushikonda, Visakhapatnam-530 003, India

<sup>3</sup>School of Chemistry, Andhra University, Visakhapatnam-530 003, India

\*Corresponding author: E-mail: [krajeswari@kluniversity.in](mailto:krajeswari@kluniversity.in)

Received: 22 April 2017;

Accepted: 28 July 2017;

Published online: 29 September 2017;

AJC-18560

In this study, the compound flavone of mangrove plant *Excoecaria agallocha* was subjected to cytotoxicity studies using Hela cells was produced from ATCC, stock cells was cultured in Dulbecco's Modified Eagle medium (DMEM) supplemented with 10 % inactivated fetal bovine serum (FBS), penicillin (100 IU/mL), streptomycin (100 µg/mL) in an humidified atmosphere of 5 % CO<sub>2</sub> at 37 °C until confluent. The cell was dissociated with trypsin phosphate versene glucose (TPVG) solution (0.2 % trypsin, 0.02% EDTA, 0.05 % glucose in PBS). The viability of the cells are checked and centrifuged. Further 50,000 cells/well was seeded in a 96 well plate and incubated for 24 h. At 37 °C, 5 % CO<sub>2</sub> incubator, it was observed that while concentration increases, the inhibition increases. Finally, the compound showing good activity in Hela cells. Docetaxel was used as standard drug.

**Keywords:** *Excoecaria agallocha*, Flavone, Anticancer activity, Hela cells.

### INTRODUCTION

The boundless tropical variety *Excoecaria* is known for the generation of dangerous metabolites [1]. It is appropriated on sea-shores and edge mangroves once in a while developed for wind and ocean softens up tropical Africa and east Asia. The leaves and smooth liquid acquired from harmed branches have been utilized as a fish harm in New Caledonia and in Okinawa, the resinous wood including latex, the supposed "Okinawa-Jinko", has likewise been utilized as a substitute for the incense of agalwood [2,3]. The bark and wood of this tree have been utilized as a part of conventional solutions for tooting in Thailand [4,5]. Anjaneyulu and Rao [6,7] revealed countless diterpenoids from *n*-hexane remove and from ethyl acetic acid derivation solubles of CH<sub>3</sub>OH:CH<sub>2</sub>Cl<sub>2</sub> (1:1) concentrate of the foundations of Indian mangrove plant *Excoecaria agallocha* L. (family: Euphorbiaceae). The piscicidal constituent of the twigs and bark of *E. agallocha* local to Okinawa has been portrayed as daphnatediterpene ester excoecariatoxin. This diterpene ester and some related mixtures have likewise been gotten from the latex of *E. agallocha* in Thailand [8-10].

Naturally, *in vitro* assurance of toxic effects of unknown compounds has been performed by counting viable cells after staining with a vital dye. Different methods used are measurement of radioisotope adding as a measure of DNA synthesis, counting

by automated counters and others which rely on dyes and cellular activity. The MTT (3-[4,5-dimethylthiazo-2-yl]-2,5-diphenyl tetrazolium bromide) system is a means of grading the activity of living cells *via* mitochondrial dehydrogenases [11-15]. The MTT method is simple, accurate and yields reproducible results. The key component is (3-[4,5-dimethylthiazo-2-yl]-2,5-diphenyl tetrazolium bromide) (MTT), is a water dissolved in tetrazolium salt yielding a yellowish solution when processed in media or salt solutions lacking phenol red [16]. Dissolved MTT is replaced to an insoluble purple formazan by cleavage of the tetrazolium ring by mitochondrial dehydrogenase enzymes of viable cells. This water insoluble formazan can be solubilized using DMSO, acidified isopropanol or other solvents (pure propanol or ethanol). The resulting purple solution is spectrophotometrically measured. An increase or decrease in cell number results in a concomitant change in the amount of formazan formed, illustrating the degree of cytotoxicity caused by the test material.

The objective of the current study is to find the sensitivity of Hela cell lines against flavone as observed inhibitory activity of flavone on the proliferation of both the cells.

### EXPERIMENTAL


**Preparation of test solutions:** The MTT powder solution is filtered through a 0.2 µm filter and stored at 2-8 °C for use. For cytotoxicity studies, each test molecule was weighed and

mixed to obtain the desired concentration and soluble in distilled DMSO and volume was made up with Dulbecco's Modified Eagle medium (DMEM) supplemented with 2 % inactivated fetal bovine serum (FBS) to obtain a stock solution of 1 mg/mL concentration and sterilized by filtration. Serial two fold dilutions (0-320 µg/mL) were prepared from this for carrying out the cytotoxic studies.

**Cell lines and culture medium:** Hela Cells was produced from ATCC, stock cells was cultured in DMEM medium supplemented with 10 % inactivated fetal bovine serum (FBS), penicillin (100 IU/mL), streptomycin (100 µg/mL) in an humidified atmosphere of 5 % CO<sub>2</sub> at 37 °C until confluent. The cell was dissociated with trypsin phosphate versene glucose (TPVG) solution (0.2 % trypsin, 0.02 % EDTA, 0.05 % glucose in PBS). The viability of the cells are checked and centrifuged. Further, 50,000 cells/well was seeded in a 96 well plate and incubated for 24 h at 37 °C at 5 % CO<sub>2</sub> incubator.

## RESULTS AND DISCUSSION

8-Hydroxy-2-(3-hydroxy-4-methoxy phenyl)-4-oxo-3-propoxy-4H-chromen-7-yl-propionate (**1**): m.p. 110 °C, m.f. C<sub>38</sub>H<sub>54</sub>O<sub>8</sub> [17]. UV (CHCl<sub>3</sub>) λ<sub>max</sub> 270 nm indicates the presence of conjugated-enone. IR (KBr, ν<sub>max</sub>, cm<sup>-1</sup>): 3534 (-OH), 2918, 2850 (-C-H), 1710 (>C=O), 1513, 1464, 1267 (-Asr group), 1174, 755 (aliphatic cyclic chain). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.6 (d, 1H, J = 16 Hz), 7.1 (dd, 1H, J = 3.6 Hz), 7.0 (dd, 1H, J = 1.6 Hz), 6.9 (d, 1H, J = 8 Hz), 6.3 (d, 1H, J = 16 Hz), 4.2 (t, 2H, J = 6.8 Hz), 3.9 (s, 3H), 2.4-2.3 (t, 3H, 7.6 Hz), 1.7-1.5 (m), 1.4-1.2 (m), 0.9 (t, 9H, 6.4 Hz). <sup>13</sup>C NMR (400 MHz, CDCl<sub>3</sub>): δ 178.0, 167.4, 148, 146.8, 144.6, 127.1, 123, 115.8, 114.7, 109.4, 77.3, 77, 76.7, 64.6, 63.1, 56, 33, 32, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 29.1, 28.8, 26, 25.7, 24.7. M+1 = 639.



Structure of 8-hydroxy-2(3-hydroxy-4-methoxy phenyl) 4-oxo-3-propoxy-4H-chromen-7-yl-propionate (**1**)

The monolayer cell culture was trypsin zed and cell count was adjusted to  $1.0 \times 10^5$  cells/mL using DMEM containing 10 % fetal bovine serum (FBS). To each well of 96 well micro-titer plate, 100 µL of the diluted cell suspension (50,000 cells/well) was added. After 24 h a partial monolayer was formed, the supernatant was flicked off, washed the monolayer once with medium and 100 µL of opposed test concentrations of test drugs were added on to the limited monolayer in microtiter

plates. The plates were then incubated at 37 °C for 3 days in 5 % CO<sub>2</sub> atmosphere, further microscopic observations were noted for every 24 h. After 72 h, the test solutions in the wells were discarded and 50 µL of MTT (5 mg/10 mL of MTT in PBS) was added to each well. The plates were gently shaken and incubated for 4 h at 37 °C at 5 % CO<sub>2</sub> atmosphere. The supernatant was removed and 100 µL of DMSO was added and the plates were gently shaken to solubilize the formed formazan. The absorbance was consistent using a microplate reader at a wavelength of 540 nm. The percentage growth inhibition was calculated using the following formula and concentration of drug desired to inhibit cell growth by 50 % (IC<sub>50</sub>) values is generated from the dose-response curves for each cell line.

$$\text{Inhibition (\%)} = \frac{(\text{OD of control} - \text{OD of sample})}{\text{OD of control}} \times 100$$

The compound **1** has shown good activity in Hela cells at different concentrations as shown in the following Table-1. The IC<sub>50</sub> found to be 123.2 mg/mL, it has been observed that the inhibition increases with the concentration increases. Similarly, compound **1** has shown 28 and 34 % acts as 160 and 320 mg/mL concentration, respectively. Hence, the compound seems to be more active in Hela cells.

TABLE-1  
HELA-CELLS

Compound name	Conc. (µg/mL)	OD at 590 nm	Inhibition (%)	IC <sub>50</sub>
Flavone	Control	0.6312	0.00	123.2
Flavone	10	0.5993	5.05	
Flavone	20	0.5667	10.22	
Flavone	40	0.4923	22.01	
Flavone	80	0.4085	35.28	
Flavone	160	0.2906	53.96	
Flavone	320	0.2003	68.27	

## Conclusion

The anticancer screening of flavone isolated from the root of *Excoecaria agallocha* using Hela cells is conducted. It is found that the flavone compound shows a good activity in Hela cells.

## ACKNOWLEDGEMENTS

The authors are thankful to Department of Chemistry, K.L. University, Guntur, India for providing the necessary research facilities.

## REFERENCES

1. K.L. Erickson, J.A. Beutler, J.H. Cardellina, J.B. McMahon, D.J. Newman and M.R. Boyd, *J. Nat. Prod.*, **58**, 769 (1995); <https://doi.org/10.1021/np50119a020>.
2. T. Konishi, M. Azuma, R. Itoga, S. Kiyosawa, Y. Fujiwara and Y. Shimada, *Chem. Pharm. Bull. (Tokyo)*, **44**, 229 (1996); <https://doi.org/10.1248/cpb.44.229>.
3. T. Konishi, S. Kiyosawa, T. Konoshima and Y. Fujiwara, *Chem. Pharm. Bull. (Tokyo)*, **44**, 2100 (1996); <https://doi.org/10.1248/cpb.44.2100>.
4. T. Konishi, T. Konoshima, Y. Fujiwara, S. Kiyosawa, K. Miyahara and M. Nishi, *Chem. Pharm. Bull. (Tokyo)*, **47**, 456 (1999); <https://doi.org/10.1248/cpb.47.456>.

5. Z.C. Wang, Y. Lin, D.Q. Feng, C.H. Ke, P. Lin, C.L. Yan and J.D. Chen, *Molecules*, **14**, 414 (2009); <https://doi.org/10.3390/molecules14010414>.
6. A.S.R. Anjaneyulu and V. Lakshmana Rao, *Phytochemistry*, **62**, 585 (2003); [https://doi.org/10.1016/S0031-9422\(02\)00269-8](https://doi.org/10.1016/S0031-9422(02)00269-8).
7. A.S.R. Anjaneyulu and V.L. Rao, *Phytochemistry*, **55**, 891 (2000); [https://doi.org/10.1016/S0031-9422\(00\)00251-X](https://doi.org/10.1016/S0031-9422(00)00251-X).
8. T. Konishi, T. Konoshima, T. Maoka and Y. Fujiwara, *Tetrahedron Lett.*, **41**, 3419 (2000); [https://doi.org/10.1016/S0040-4039\(00\)00391-9](https://doi.org/10.1016/S0040-4039(00)00391-9).
9. S.P.M. Crouch, R. Kozlowski, K.J. Slater and J. Fletcher, *J. Immunol. Methods*, **160**, 81 (1993); [https://doi.org/10.1016/0022-1759\(93\)90011-U](https://doi.org/10.1016/0022-1759(93)90011-U).
10. R.J. Gonzalez and J.B. Tarloff, *Toxicol. in Vitro*, **15**, 257 (2001); [https://doi.org/10.1016/S0887-2333\(01\)00014-5](https://doi.org/10.1016/S0887-2333(01)00014-5).
11. N. Hattori, T. Sakakibara, N. Kajiyama, T. Igarashi, M. Maeda and S. Murakami, *Anal. Biochem.*, **319**, 287 (2003); [https://doi.org/10.1016/S0003-2697\(03\)00322-1](https://doi.org/10.1016/S0003-2697(03)00322-1).
12. L. Kangas, A.L. Nieminen and M. Grönroos, *Med. Biol.*, **62**, 338 (1984).
13. A. Lundin, M. Hasenson, J. Persson and Å. Pousette, *Methods Enzymol.*, **133**, 27 (1986); [https://doi.org/10.1016/0076-6879\(86\)33053-2](https://doi.org/10.1016/0076-6879(86)33053-2).
14. Cell Viability and Prolifiration, *BioFiles*, vol. 6, no. 5, pp. 17-21.
15. F. Denizot and R. Lang, *J. Immunol. Methods*, **89**, 271 (1986); [https://doi.org/10.1016/0022-1759\(86\)90368-6](https://doi.org/10.1016/0022-1759(86)90368-6).
16. T. Mosmann, *J. Immunol. Methods*, **65**, 55 (1983); [https://doi.org/10.1016/0022-1759\(83\)90303-4](https://doi.org/10.1016/0022-1759(83)90303-4).